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Abstract 
Acute  gastroenteritis  is  one  of  the  most
common infectious diseases of childhood. Its
symptoms are vomiting, diarrhea, and dehy-
dration. In the emergency ward, intravenous
rather  than  oral  rehydration  is  usually  pre-
ferred because of the high likelihood of eme-
sis. Treatments to reduce emesis are of value
in improving the rehydration procedure. Our
study is a double-blind randomized trial and
proposes the use of ondansetron as an anti-
emetic drug to treat children with acute gas-
troenteritis.  Seventy-four  in-patients,  aged  3
months to 15 years, were enrolled and random-
ly  assigned  to  an  ondansetron  or  placebo
group. Inclusion criteria were the diagnosis of
acute gastroenteritis and the absence of other
diseases or allergies to drugs. A single bolus
(0.15  mg/kg)  of  ondansetron  was  injected
intravenously; normal 0.9% saline solution was
used  as  a  placebo.  This  treatment  induced
vomiting cessation in the ondansetron group
significantly  in  comparison  to  the  placebo
group. The length of the hospital stay and the
oral rehydration fluid volume were similar in
the two groups and no adverse effects were
noticed.  Thus,  safety,  low  cost,  and  overall
bene  fit  of  ondansetron  treatment  suggests
that this drug can be administered successful-
ly to children with acute gastroenteritis.
Introduction
Acute gastroenteritis is a common illness in
childhood.  Frequently  caused  by  viruses,  its
symptoms include vomiting, diarrhea, abdom  -
inal pain, and fever. No therapy is suggested
for viral infections, while dehydration caused
by diarrhea and emesis should be treated vig-
orously.
1 In  emergency  departments,  physi-
cians  usually  choose  intravenous  over  oral
rehydration when vomiting is the most impor-
tant symptom, even if oral rehydration is rec-
ommended for mild to moderate dehydration.
2
Thus,  reducing  emesis  is  the  first  goal  to
assure the preference and the success rate of
oral  dehydration.
3 Anti-emetic  treatments
could  have  potential  benefits  but  some  con-
cerns about the adverse effects, such as extra-
pyramidal  symptoms  or  lethargy,  discourage
their use.
4 Ondansetron is a novel anti-emetic
drug currently used to treat nausea and vomit-
ing associated with antineoplastic therapies in
children and adults.
5 Its activity as a serotonin
5-HT3  receptor  antagonist  prevents  extra-
pyramidal  effects.
5 For  this  reason,  ondan  -
setron has been studied for a possible use in
acute gastroenteritis in children. Ondansetron
has shown greater effectiveness in reducing
vomiting  when  compared  with  metoclo-
pramide, a common anti-emetic or placebo, but
has  an  increased  incidence  of  diarrhea.
6
Furthermore, intravenous ondansetron admin-
istration in a double-blind trial in the emer-
gency  department  has  significantly  reduced
emesis,  diarrhea,  and  hospital  admission
rates, confirming the cost-benefit ratio associ-
ated  with  this  pharmaceutical  approach.
7
Based on this preliminary evidence, our pres-
ent study shows the result of a single dose of
intravenous ondansetron in the in-patient set-
ting in Thai children.
Materials and Methods
Our study was a prospective, double-blind,
randomized comparison between ondansetron
and  a  placebo  to  reduce  emesis  in  children
affected by acute gastroenteritis. The trial was
conducted at the pediatric in-patient ward of
the Srinakharinwirot University Hospital from
January  2008  to  October  2008.  The  Ethics
Committee of the Faculty of Medicine at the
Srinakharinwirot University approved the pro-
tocol  study.  Children,  from  3  months  to  15
years old, who vomited more than three times
in the 24 hours prior to admission and had
acute gastroenteritis symptoms, were eligible
for  the  study.  Parents  or  legal  guardians  of
children who met eligible criteria were asked
to  sign  a  written  informed  consent  form.
Treatment with any anti-emetic drug within 24
hours  before  enrolment  or  any  history  of  a
chronic medical condition such as hepatic dis-
ease, cardiovascular disease, chronic respira-
tory disease, immunodeficiency, tumors, dia-
betes mellitus, chronic gastrointestinal condi-
tions,  behavioral  or  psychiatric  problems,  or
other neurological conditions were considered
as exclusion criteria. Children who had a his-
tory of any drug allergy were also excluded.
After enrolment, demographic characteristics
and  clinical  data  were  recorded  by  nursing
staff. Weight to the nearest 100 g and height to
the nearest millimeter were measured. To clas-
sify  the  hydration  status,  the  World  Health
Organization criteria were adopted on admis-
sion; Table 1 summarizes the scale.
Participants were randomized in two groups
by a computerized program using a block of
two,  and  were  assigned  to  the  ondansetron
group  or  placebo  group.  After  intravenous
blood  access  for  baseline  biochemistry  and
fluid resuscitation, patients received a single
bolus  of  intravenous  ondansetron  (Zofran,
Glaxo Wellcome Inc.) at the dose of 0.15 mg/kg
up to the maximal dose of 8 mg over 2 min.
Children  who  were  assigned  to  the  control
group were treated intravenously with 0.9% of
normal saline solution, the same amount as
the ondansetron treatment, and over 2 min as
well.  Attending  physicians  were  responsible
for the treatment protocol and discharge from
the  hospital.  The  primary  outcome  was  the
number  of  vomiting  episodes  after  drug
administration. We defined a vomiting episode
as  a  forceful  expulsion  of  stomach  contents
that was separated from the previous one by
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more  than  2  min.  Non-productive  retching,
spilling of oral contents, and drooling were not
considered vomiting. The secondary outcomes
were the volume of intravenous and oral rehy-
dration  fluid,  length  of  hospital  stay,  and
adverse  effects.  The  results  were  presented
descriptively as mean, SD, and percent values.
The Pearson chi-square or Fisher exact test
were used to compare proportions between the
two groups. Continuous variables were com-
pared by using a Student t-test. Comparison of
ordinal variables between groups was done by
the Mann-Whitney U test. Statistical analysis
was  performed  with  the  SPSS  11.0  software
package. The P-value of <0.05 was considered
as statistically significant.
Results
One hundred and eight potentially eligible
patients  were  approached  to  enroll  for  the
study. Of these, 74 patients accepted the invi-
tation to join and were randomly assigned to
two  treatment  groups:  one  treated  with
ondansetron  and  the  other  treated  with  the
placebo, as a control. The mean age was 3.2 yr
(SD 2.6; range 3 mth to 12 yr) and thirty-eight
patients (51.4%) were boys. Firstly, we evaluat-
ed  the  clinical  presentation  in  terms  of  the
mean number of vomiting episodes during the
24 hr before admission, mean onset, and last
vomiting incident before admission. Data are
reported in Table 2.
Fifty-two children (70.3%) were graded as
having  mild  dehydration  by  attending  phys  -
icians at the time of admission. There were no
significant differences in baseline characteris-
tics including demographics, clinical presenta-
tions,  and  hematological  and  biochemistry
parameters between the groups (Table 2). No
patient  had  hypernatremia  or  hypokalemia.
Severe  metabolic  acidosis  (bicarbonate  <15
mEq/L) on admission was reported in five and
two patients in the ondansetron and placebo
groups,  respectively.  Outcomes  of  treatment
are presented in Table 3. 
After  drug  administration,  30  (81.1%)
patients in the ondansetron group completely
ceased  vomiting  as  compared  to  9  (24.3%)
patients of the placebo group (P<0.01). The
mean number of vomiting episodes after drug
administration was significantly lower in the
ondansetron group than in the placebo group
(0.5 vs. 2.1, P<0.01). Median time of complete
cessation in the placebo group was 10 hr while
emesis  ceased  immediately  in  the  ondan-
setron  group.  No  significant  differences  in
length of hospital stay, volume of intravenous
fluid, and oral rehydration fluid administra-
tion were observed between the groups. We
did not observe any adverse effect in either
group. 
Brief Report
Table 1. Scale of hydration status.
Symptoms
Normal or mild dehydration No signs or symptoms
Moderate dehydration Thirsty, restless or irritable behavior, decreased skin 
elasticity, sunken eyeballs
Severe dehydration Shock or diminished consciousness, lack of urine 
output, cool and moist extremities, low blood 
pressure, rapid and feeble pulse
Table 2. Demographic description of ondansetron and placebo groups.
Ondansetron Placebo
(N=37) (N=37)
Age (yr); mean±SD 3.4±2.8 3.0±2.5
Median (range) 2.6 (0.3-12.0) 2.3 (0.3-10.4)
% Boy 21 (56.8) 17 (45.6)
Weight (kg) 14.9±6.1 12.8±4.2
Height (cm) 97.4±16.6 92.7±20.0
Number of vomiting in previous 24 hr; mean±SD 6.7±4.5 7.5±3.9
Last vomiting prior to admission; hr±SD 3.1±3.5 2.4±2.2
Onset of vomiting prior to admission; hr ± SD 23.2±21.6 28.4±24.6
Presence of diarrhea; n (%) 18 (48.6) 27 (73.0)
Number of diarrhea episodes in previous 24 hr; median (range) 4.2±3.0 6.1±4.7
Fever >38.5°C; n (%) 3 (8.1) 7 (18.9)
Previous visit to a physician; n (%) 17 (45.9) 20 (54.0)
Hydration status; n (%)
Mild or no dehydration 26 (70.3) 26 (70.3)
Moderate dehydration 11 (29.7) 11 (29.7)
Sodium (mEq/L) 134.7±2.1 135.8±3.3
Potassium (mEq/L) 4.2±0.4 4.1±0.7
Bicarbonate (mEq/L) 18.9±4.1 18.5±3.7
BUN 15.0±5.0 13.5±5.5
Creatinine 0.5±0.2 0.5±0.2
Urine specific gravity 1.018±0.005 1.017±0.006
Hematocrit (%) 34.8±2.5 35.4±3.3
Hemoglobin (g/dL) 11.8±0.9 12.0±1.4
White blood cell count 9439±4587 9299±5620
Table 3. Outcomes measurements.
Ondansetron Placebo P
(N=37) (N=37)
Number of vomiting episodes; n (%)
Mean±SD 0.5±.2 2.1±1.9 <0.01
Median (range) 0 (0-5) 2 (0-7) <0.01
Cessation of vomiting 30 (81.1) 9 (24.3) <0.01
1 episode 3 (8.1) 5 (13.5)
2 episodes 1 (2.7) 10 (27.0)
≥3 episodes 3 (8.1) 13 (35.1)
Last vomiting after drug administration; hr
Mean±SD 4.2±11.3 13.5±13.6 <0.01
Median (range) 0 (0-53) 10 (0-56) <0.01
Intravenous fluid received (mL/kg/hr); mean±SD 4.3±1.3 4.1±1.4 0.65
Oral rehydration solution (mL/kg/hr); mean±SD 1.9±1.7 1.3±1.0 0.15
Length of hospital stay (hr); mean±SD 53.8±61.3 60.5±46.6 0.60[Pediatric Reports 2010; 2:e17] [page 57]
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Discussion
Our study provides evidence that an intra-
venous dose of ondansetron could be useful in
reducing emesis associated to acute gastroen-
teritis. We have investigated 74 children, aged
from  3  months  to  15  years,  admitted  to  the
pediatric ward with a diagnosis of moderate or
severe  dehydration,  in  accordance  with  the
World  Health  Organization  guidelines.
Previous  studies  enrolled  children  as  out-
patients;
7,8however, we chose to enroll children
in the in-patient setting in order to minimize
the  difference  in  the  rehydration  procedure
and,  in  general,  in  overall  treatment.
Furthermore,  we  reduced  the  interference
from a single physician by counting the num-
ber of vomiting episodes after treatment and
complete  emesis  cessation  as  primary  out-
comes. In addition, we analyzed the length of
hospital stay, volume of intravenous fluid, and
oral  fluid  administration  as  secondary  out-
comes, without observing any significant dif-
ferences between the ondansetron and placebo
groups. 
Results reported in our study show agree-
ment with those of previous clinical studies
conducted in the emergency department. We
decided  to  use  a  single  intravenous  dose
because no solution is available for this med-
ication and it may have been difficult to orally
administer  a  tablet  to  young  children.
Intravenous  ondansetron  treatment  (0.15
mg/kg)  favors  vomiting  cessation  in  70%  of
patients in comparison to 51% of the placebo
group and, consequently, reduces the need for
admission to the pediatric ward.
7 This positive
effect may compensate for the cost of the drug,
which  is  not  cheap.  Furthermore,  oral
ondansetron  treatment  shows  that  children
vomit less often and tolerate an oral rehydra-
tion  procedure  better.
8 In  addition,  a  higher
mean  incidence  of  diarrhea  in  an  oral
ondansetron group has been described, while
intravenous  treatment  seems  to  decrease
episodes of diarrhea.
7,8 There is no evidence of
other adverse effects in cardiovascular or res-
piratory  systems.
8 A  possible  limitation  of
these studies is the inclusion criteria; indeed,
considering a set number of vomiting episodes
within  the  previous  24  hours  could  have
included patients with milder cases of acute
gastroenteritis, inducing a too optimistic eval-
uation of the ondansetron treatment. However,
current evidence demonstrates clinical bene-
fits in the use of ondansetron as an anti-emet-
ic in children with acute gastroenteritis.
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